West Pharmaceutical said on Tuesday, December 9, 2024, its Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of common stock on the open market or in privately negotiated transactions.

8-KOther EventsFiled Dec 13, 2024Period of report Dec 9, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

West Pharmaceutical said on Tuesday, December 9, 2024, its Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of common stock on the open market or in privately negotiated transactions.
The company said purchases under the program may be made on the open market or in privately negotiated transactions, as permitted under Exchange Act Rule 10b-18.
The company said the number of shares to be repurchased and the timing of transactions will depend on a variety of factors, including market conditions. It said the program is expected to be completed by December 31, 2025.
The company said its previously authorized share repurchase program is expected to expire by December 31, 2024.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

West Pharmaceutical approves 550,000-share buyback program

West Pharmaceutical said on Tuesday, December 9, 2024, its Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of common stock on the open market or in privately negotiated transactions.

Source · Based on the filing body and exhibits

Repurchases to be made within Exchange Act Rule 10b-18

The company said purchases under the program may be made on the open market or in privately negotiated transactions, as permitted under Exchange Act Rule 10b-18.

Source · Based on the filing body and exhibits

Timing and number of shares to depend on market conditions

The company said the number of shares to be repurchased and the timing of transactions will depend on a variety of factors, including market conditions. It said the program is expected to be completed by December 31, 2025.

Source · Based on the filing body and exhibits

Existing buyback program to expire at end of 2024

The company said its previously authorized share repurchase program is expected to expire by December 31, 2024.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.